Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10426039 | 1.00 | DGKA (0.72) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL8024637 | 1.00 | DGKA (0.72) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL9570462 | 1.00 | DGKA (0.72) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL6469329 | 0.98 | DGKA (0.69) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL10030735 | 0.97 | DGKA (0.68) | DGKATSHRHPGDDNM1ALDH1A1 | |
| Propene SCHEMBL19717884 | 0.97 | DGKA (0.68) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL23553096 | 0.95 | DGKA (0.66) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL14792967 | 0.95 | DGKA (0.66) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL10426125 | 0.95 | TSHR (0.68) | DGKATSHRHPGDDNM1ALDH1A1 | |
| SCHEMBL2610338 | 0.93 | TSHR (0.69) | DGKATSHRHPGDDNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653153-B1 | Violet curable ink | XEROX CORPORATION (US) | 2014-02-18 | — | — | US | disclosed |
| US-8142557-B2 | Radiation curable ink containing gellant and radiation curable wax | XEROX CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-7887176-B2 | High image quality in inkjet printing onto flexible packaging substrates of polyester, polypropylene, and aluminum foil, can be significantly improved by the use of radiation curable gel based phase change inks; not requiring pinning of the ink during color printing or nitrogen inerting during curing | XEROX CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100242790-A1 | CATIONICALLY AND HYBRID CURABLE UV GELS | XEROX CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-7714040-B2 | Phase change inks containing curable amide gellant compounds | XEROX CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7531582-B2 | Radiation curable phase change inks containing curable epoxy-polyamide composite gellants | XEROX CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080122914-A1 | RADIATION CURABLE PHASE CHANGE INKS CONTAINING CURABLE EPOXY-POLYAMIDE COMPOSITE GELLANTS | XEROX CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080000384-A1 | RADIATION CURABLE INK CONTAINING GELLANT AND RADIATION CURABLE WAX | XEROX CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| US-7279587-B2 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-7276614-B2 | Curable amide gellant compounds | XEROX CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7271284-B2 | Process for making curable amide gellant compounds | XEROX CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7259275-B2 | Method for preparing curable amide gellant compounds | XEROX CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070123606-A1 | Phase change inks containing curable amide gellant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123724-A1 | Method for preparing curable amide gellant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123663-A1 | Process for making curable amide gellant compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123722-A1 | Ester-terminated oligoamides and polyamides having terminal ethylenic double bonds; gelling agents for phase change ink jet inks with improved ultraviolet curability and solubility | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123724-A1 | Method for preparing curable amide gellant compounds | ODC1, INO80C, AOC1 | DGKA 1213/4885TSHR 2143/4885HPGD 611/4885 |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | DGKA 3288/4885TSHR 288/4885HPGD 3228/4885 |
| US-20070123722-A1 | Ester-terminated oligoamides and polyamides having terminal ethylenic double bonds; gelling agents for phase change ink jet inks with improved ultraviolet curability and solubility | CCNA2, ELL, CCNA1 | DGKA 3286/4885TSHR 3048/4885HPGD 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.